ESMO-GC 2021 - ESMO GYNAECOLOGICAL CANCERS 2021 (VIRTUAL MEETING)
Jun 25 - Jun 26, 2021 | LuganoSwitzerland
LARVOL is not affiliated with ESMO GYNAECOLOGICAL CANCERS 2021 (VIRTUAL MEETING) and all trademarks, logos, and brand names are property of their respective owners
Showing 4 titles linked to Trials
[VIRTUAL] Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
[VIRTUAL] Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation
[VIRTUAL] Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study
[VIRTUAL] Long term safety and secondary efficacy end points in the ENGOT-OV16/NOVA phase 3 trial on Niraparib in recurrent ovarian cancer